Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives
09 mai 2024 07h30 HE
|
Attovia Therapeutics, Inc.
-- Proceeds support advancing Attovia’s lead programs through initial clinical readouts, expanding its pipeline, and ongoing development of the ATTOBODY™ platform -- Financing led by Goldman Sachs...
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
09 mai 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics today reported business highlights and financial results for the first quarter ending March 31, 2024.
Medigene to Present at Upcoming Conferences
07 mai 2024 09h00 HE
|
Medigene AG
Planegg/Martinsried, May 7, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
02 mai 2024 04h30 HE
|
Medigene AG
Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
02 mai 2024 02h30 HE
|
Medigene AG
Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA® (guselkumab) for treatment of patients with ulcerative colitis and Crohn’s disease
01 mai 2024 06h55 HE
|
Janssen Cilag International NV
Media contact:Sophie DaneauSdaneau@its.jnj.com+33 6 3178 8798Investor contact:Raychel Kruperinvestor-relations@its.jnj.com For European and UK medical and trade media only For immediate...
Congresso da EAACI 2024: Inovação e Avanços no Tratamento da Alergia
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
Durante o congresso serão apresentadas mais de 150 sessões científicas, centradas nos avanços da ciência ambiental, alergias alimentares, inovações em imunoterapia e alergias pediátricas, entre...
EAACI Congress 2024: Innovationen und Fortschritte in der Allergietherapie
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
Im Rahmen des Kongresses werden über 150 wissenschaftliche Vorträge gehalten, die sich unter anderem mit Fortschritten in den Bereichen Umweltwissenschaft, Lebensmittelallergien, Innovationen in der...
EAACI Congress 2024：創新與過敏治療進展
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
大會期間將呈獻超過 150 場科學會議，重點關注環境科學、食物過敏、免疫療法創新和兒童過敏等方面的進展。精準醫療、AI、免疫療法和免疫調節劑將匯聚在此次最大型的過敏和免疫學大會上。大會將於 5 月 31 日至 6 月 3 日在西班牙華倫西亞舉行。 華倫西亞，西班牙, April 30, 2024 (GLOBE NEWSWIRE) -- 歐洲過敏和臨床免疫學會 (European...
EAACI Congress 2024: Innovation and Advances in Allergy Treatment
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
The EAACI 2024 Congress, by the European Academy of Allergy and Clinical Immunology (EAACI) in Valencia, Spain, from May 31st to June 3rd.